These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38512627)

  • 61. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma.
    Granata V; Fusco R; Venanzio Setola S; Sandomenico F; Luisa Barretta M; Belli A; Palaia R; Tatangelo F; Grassi R; Izzo F; Petrillo A
    Radiol Oncol; 2020 May; 54(2):149-158. PubMed ID: 32463393
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A gadoxetic acid-enhanced MRI-based model using LI-RADS v2018 features for preoperatively predicting Ki-67 expression in hepatocellular carcinoma.
    Liang Y; Xu F; Mou Q; Wang Z; Xiao C; Zhou T; Zhang N; Yang J; Wu H
    BMC Med Imaging; 2024 Jan; 24(1):27. PubMed ID: 38273242
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response.
    Abdelrahman AS; Ekladious MEY; Badran EM; Madkour SS
    Diagn Interv Imaging; 2022 Nov; 103(11):524-534. PubMed ID: 35787988
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma.
    Cannella R; Vernuccio F; Sagreiya H; Choudhury KR; Iranpour N; Marin D; Furlan A
    Eur Radiol; 2020 Jul; 30(7):3770-3781. PubMed ID: 32107603
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI.
    Cha H; Choi JY; Park YN; Han K; Jang M; Kim MJ; Park MS; Rhee H
    Eur Radiol; 2023 Feb; 33(2):1364-1377. PubMed ID: 35999373
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Incorporation of Ancillary MRI Features Into the LI-RADS Treatment Response Algorithm: Impact on Diagnostic Performance After Locoregional Treatment of Hepatocellular Carcinoma.
    Kim YY; Kim MJ; Yoon JK; Shin J; Roh YH
    AJR Am J Roentgenol; 2022 Mar; 218(3):484-493. PubMed ID: 34585608
    [No Abstract]   [Full Text] [Related]  

  • 67. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS.
    Hu YX; Shen JX; Han J; Mao SY; Mao RS; Li Q; Li F; Guo ZX; Zhou JH
    Front Oncol; 2021; 11():641195. PubMed ID: 33912456
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
    Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
    Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
    [TBL] [Abstract][Full Text] [Related]  

  • 69. LI-RADS v2017 categorisation of HCC using CT: Does moderate to severe fatty liver affect accuracy?
    Kim SS; Hwang JA; Shin HC; Choi SY; Kang TW; Jou SS; Lee WH; Park S; Heo NH
    Eur Radiol; 2019 Jan; 29(1):186-194. PubMed ID: 30073499
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Diabetes Mellitus and/or Nonalcoholic Steatohepatitis-related Hepatocellular Carcinoma Showed Favorable Surgical Outcomes After Hepatectomy.
    Liang J; Ariizumi SI; Nakano M; Yamamoto M
    Anticancer Res; 2019 Oct; 39(10):5639-5643. PubMed ID: 31570461
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pathological overview of steatohepatitic hepatocellular carcinoma in a surgical series.
    Trapani L; Beaufrère A; Hobeika C; Codjia T; Albuquerque M; Bouattour M; Lesurtel M; Cauchy F; Paradis V
    Histopathology; 2023 Oct; 83(4):526-537. PubMed ID: 37222200
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
    Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
    Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis.
    van der Pol CB; McInnes MDF; Salameh JP; Levis B; Chernyak V; Sirlin CB; Bashir MR; Allen BC; Burke LMB; Choi JY; Choi SH; Forner A; Fraum TJ; Giamperoli A; Jiang H; Joo I; Kang Z; Kierans AS; Kang HJ; Khatri G; Kim JH; Kim MJ; Kim SY; Kim YY; Kwon H; Lee JM; Lewis SC; McGinty KA; Mulazzani L; Park MS; Piscaglia F; Podgórska J; Reiner CS; Ronot M; Rosiak G; Song B; Song JS; Tang A; Terzi E; Wang J; Wang W; Wilson SR; Yokoo T
    Radiology; 2022 Feb; 302(2):326-335. PubMed ID: 34783596
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
    Lee S; Kim MJ; Kim SS; Shin H; Kim DY; Choi JY; Park MS; Mitchell DG
    Hepatol Int; 2020 Jan; 14(1):70-79. PubMed ID: 31802388
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS.
    Choi SJ; Choi SH; Kim DW; Kwag M; Byun JH; Won HJ; Shin YM
    J Hepatol; 2023 Mar; 78(3):596-603. PubMed ID: 36402451
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Percentages of Hepatocellular Carcinoma in LI-RADS Categories with CT and MRI: A Systematic Review and Meta-Analysis.
    Lee S; Kim YY; Shin J; Son WJ; Roh YH; Choi JY; Sirlin CB; Chernyak V
    Radiology; 2023 Apr; 307(1):e220646. PubMed ID: 36625748
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Per-patient Negative Predictive Value of the CT and MRI Liver Imaging Reporting and Data System Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma.
    Hassan OT; Behr SC; Ohliger MA; Fowler KJ; Gill RM; Fidelman N; Mehta N; Choi HH
    Radiology; 2023 Dec; 309(3):e222776. PubMed ID: 38112541
    [TBL] [Abstract][Full Text] [Related]  

  • 78. β-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study.
    Ando S; Shibahara J; Hayashi A; Fukayama M
    Virchows Arch; 2015 Nov; 467(5):535-42. PubMed ID: 26311355
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
    Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
    Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
    Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
    J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.